RNASE3 gene – Talk Bio

Actionable Insights Powered by AI

TCT 2024: Johnson & Johnson’s Abiomed Successfully Completes Pivotal Study for Innovative Shrinkable Heart Pump, Impella ECP

6 months ago talkbio0Tagged Abiomed, Approved, High-Risk PCI, Impella, Johnson & Johnson, RNASE3 gene, Shock, Cardiogenic, Shrinkable Heart Pump, Thrombin Time Assay, United States Food and Drug Administration

TCT 2024, Johnson & Johnson, Abiomed, Impella ECP, Shrinkable Heart Pump, High-Risk PCI, Cardiogenic Shock, FDA Approval

Mallinckrodt to Sell Therakos Business Unit to CVC Capital for $925 Million

9 months ago talkbio0Tagged Capital Partners, central venous catheter (CVC) sets, Extracorporeal, Healthcare services, Immunotherapy, Lymphoma, T-Cell, Cutaneous, mallinckrodt, medical technology, Photopheresis, RNASE3 gene, Therakos

Mallinckrodt, Therakos, CVC Capital Partners, photopheresis, extracorporeal photopheresis, ECP, cutaneous T-cell lymphoma, CTCL, immunotherapy, pharmaceuticals, medical technology, healthcare services